Oncology software assets change hands

Article

Varian Medical Systems has acquired the assets of Denver-based OpTx, a privately held supplier of software for medical oncology practices. Varian, which paid approximately $18 million cash to obtain the assets, plans to continue to develop, sell,

Varian Medical Systems has acquired the assets of Denver-based OpTx, a privately held supplier of software for medical oncology practices. Varian, which paid approximately $18 million cash to obtain the assets, plans to continue to develop, sell, install, and service OpTxTools software worldwide as a stand-alone product for medical oncology practices and as part of its VARiS software for coordination with radiation oncology. With this acquisition, Varian is able to offer an integrated single software system for managing and coordinating radiation therapy and chemotherapy routinely used in the treatment of cancer, according to the company. The acquisition is expected to add annualized revenues of $9 million to Varian coffers and be nearly neutral to earnings for the company in fiscal year 2004.

Recent Videos
Study: MRI-Based AI Enhances Detection of Seminal Vesicle Invasion in Prostate Cancer
What New Research Reveals About the Impact of AI and DBT Screening: An Interview with Manisha Bahl, MD
Can AI Assessment of Longitudinal MRI Scans Improve Prediction for Pediatric Glioma Recurrence?
A Closer Look at MRI-Guided Adaptive Radiotherapy for Monitoring and Treating Glioblastomas
Incorporating CT Colonography into Radiology Practice
What New Research Reveals About Computed Tomography and Radiation-Induced Cancer Risk
What New Interventional Radiology Research Reveals About Treatment for Breast Cancer Liver Metastases
New Mammography Studies Assess Image-Based AI Risk Models and Breast Arterial Calcification Detection
Can Deep Learning Provide a CT-Less Alternative for Attenuation Compensation with SPECT MPI?
Employing AI in Detecting Subdural Hematomas on Head CTs: An Interview with Jeremy Heit, MD, PhD
Related Content
© 2025 MJH Life Sciences

All rights reserved.